EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Emerging Tests for Noninvasive Colorectal Cancer Screening

Marina Hanna, Neelendu Dey, William M Grady

Clinical Gastroenterology and Hepatology · 2023-03 · 21 (3) · 604-616

DOI: 10.1016/j.cgh.2022.12.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-03. Verfasst von Marina Hanna und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington, Seattle, Washington. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute Division of Cancer Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is among the most common cancers globally and a major cause of cancer-related deaths. The American Cancer Society estimates that CRC will kill 1 in 60 Americans, and CRC screening is recommended for all Americans ≥45 years of age. Current CRC screening methods are effective for preventing CRC and have been shown to reduce CRC-related mortality. However, none of the currently available tests is ideal, and many people are not compliant with screening recommendations. Novel screening tests based on advances in CRC molecular biology, genetics, and epigenetics, combined with developments in sequencing technologies and computational analytic methods, have been developed to address the shortcomings of current CRC screening tests. These emerging tests include blood-based assays that use plasma-derived circulating tumor DNA and serum proteins to detect early CRC and advanced adenomas, assays that use stool DNA or mRNA, and methods for profiling the gut microbiome. Here we review current screening modalities, and we discuss the principles behind the most promising emerging CRC screening tests and the data supporting their potential to be used in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCirculating Tumor DNAHumansColonoscopyEarly Detection of CancerMass Screening

Stichwörter der Autor:innen

Colorectal CancerEpigeneticsGeneticsMicrobiomeScreening

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Department of Medicine, University of Washington, Seattle, Washington.
  • Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Microbiome Research Initiative, Fred Hutchinson Cancer Center, Seatt…
  • Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. Electronic address: wgrady@fredhutch.org.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute Division of Cancer Prevention

Zitieren

APA

Hanna, M., Dey, N., & Grady, W. M. (2023). Emerging Tests for Noninvasive Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 21(3), 604-616. https://doi.org/10.1016/j.cgh.2022.12.008

Vancouver

Hanna M, Dey N, Grady WM. Emerging Tests for Noninvasive Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology. 2023;21(3):604-616. doi:10.1016/j.cgh.2022.12.008

BibTeX
@article{Hanna2023,
  author = {Hanna, Marina and Dey, Neelendu and Grady, William M},
  title = {Emerging Tests for Noninvasive Colorectal Cancer Screening},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {3},
  pages = {604--616},
  doi = {10.1016/j.cgh.2022.12.008}
}
Kostenlos starten →